Are antiretroviral switch or simplification studies of benefit for patients?
Australians find that money problems lead to poorer adherence to HIV therapy
US youth, heterosexual men and African Americans losing out on HIV treatment benefits
Starting HIV treatment reduces risk of tuberculosis, even for patients with higher CD4 cell counts
Higher CD4 count preserves ability to work and educate children
Raltegravir 800mg twice daily appears a good alternative to efavirenz for HIV-TB treatment
Once-daily elvitegravir works as well as raltegravir at 96 weeks
Cobicistat matches ritonavir as atazanavir booster
First generic HIV drugs could save US at least $920 million a year
